Ibrutinib Becomes First FDA-Approved Drug for Chronic Graft-Versus-Host Disease

A drug used to treat several blood cancers, ibrutinib, has been approved by FDA to treat chronic graft-versus-host disease, making it the first approved therapy for this potentially fatal side effect of cancer-related stem cell transplants.

Cancer Currents: An NCI Cancer Research Blog